Impact of preoperative pharmaceutical care consultation on medication errors in surgical patients: a comprehensive analysis
CONCLUSIONS: This study highlights the effectiveness of pharmaceutical care consultations in preventing MEs and improving surgical outcomes.PMID:38063348 | DOI:10.1080/14740338.2023.2292710 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: Daniel Gomez Costas Almudena Ribed S ánchez Alvaro Gimenez Manzorro Ignacio Garutti Martinez Francisco Javier Sanz Fernandez Beatriz Torroba Sanz Sergio Herrero Bermejo Ana Mar ía Herranz-Alonso Mar ía Sanjurjo Source Type: research
Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia
Expert Opin Drug Saf. 2023 Dec 8. doi: 10.1080/14740338.2023.2293206. Online ahead of print.ABSTRACTINTRODUCTION: The drug classes of α1-adrenoceptor antagonists, 5α-reductase inhibitors, and phosphodiesterase type 5 inhibitors are guideline recommended treatments of lower urinary tract symptoms suggestive of benign prostatic hyperplasia; muscarinic receptor antagonists and β3-adrenoceptor agonists are also recommended if storage symptoms are insufficiently addressed with one of the other three drug classes.AREAS COVERED: We provide a narrative review (no formalized literature searches performed) of the tolerability of ...
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: A Elif M üderrisoglu Jean J M C H de la Rosette Martin C Michel Source Type: research
Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases
CONCLUSIONS: Our study identified signals for priapism for several anti-seizure medications, but these results need to be confirmed in well-designed pharmacoepidemiological studies.PMID:38062555 | DOI:10.1080/14740338.2023.2293208 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - December 8, 2023 Category: Drugs & Pharmacology Authors: Nemanja Z Petrovi ć Ana V Pej čić Ivan R Milovanovi ć Source Type: research
Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management
Expert Opin Drug Saf. 2023 Dec 4. doi: 10.1080/14740338.2023.2291865. Online ahead of print.ABSTRACTINTRODUCTION: In patients with an acute coronary syndrome (ACS), the ischemic benefit of antithrombotic treatment is counterbalanced by the risk of bleeding. The recognition that a bleeding event has prognostic implications (i.e. mortality) similar to a recurrent ischemic event led to the development of treatment regimens aimed at balancing both ischemic and bleeding risks.AREAS COVERED: This review aims at describing definitions, incidence and prognosis related to bleeding events in ACS patients as well as bleeding-avoidanc...
Source: Expert Opinion on Drug Safety - December 4, 2023 Category: Drugs & Pharmacology Authors: Claudio Laudani Davide Capodanno Angiolillo Dominick Joseph Source Type: research
A real-world analysis of safety profile of selexipag by using FDA adverse event Reporting System (FAERS)
CONCLUSIONS: The findings contribute valuable insights to clinical practice, reinforcing the importance of vigilant monitoring, and can be instrumental in guiding both therapeutic applications and safety assessments of this particular medication.PMID:38032065 | DOI:10.1080/14740338.2023.2290633 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - November 30, 2023 Category: Drugs & Pharmacology Authors: Jie Zhao Mei Wang Qing Yu Yi Yang Bin Zhang Sanhua Zhan Source Type: research
Nail lichen planus treatment safety
Expert Opin Drug Saf. 2023 Nov 28:1-12. doi: 10.1080/14740338.2023.2288902. Online ahead of print.ABSTRACTTopical therapies for nail lichen planus (clobetasol propionate, topical tacrolimus, bath-PUVA), intralesional treatment (triamcinolone), and systemic treatment (corticosteroids, retinoids, small molecule inhibitors (jak/stat inhibitors)), TNF-alpha inhibitors (etanercept), systemic immunomodulators (oral calcineurin inhibitors, mycophenolate mophetil), and antimalarials (chloroquine), each with unique safety profiles and considerations. Herein, we discuss common and uncommon adverse events, as well as utilization for ...
Source: Expert Opinion on Drug Safety - November 28, 2023 Category: Drugs & Pharmacology Authors: Eden N Axler Shari R Lipner Source Type: research
A comparative safety review of targeted therapies for acute myeloid leukemia
Expert Opin Drug Saf. 2023 Nov 28. doi: 10.1080/14740338.2023.2289176. Online ahead of print.ABSTRACTINTRODUCTION: Acute myeloid leukemia (AML) treatment has primarily focused on 7 + 3 chemotherapy, but in the last decade there has been a significant increase in new therapies, mostly targeted agents, approved for the treatment of AML. We performed a comparative analysis of the unique safety profile of each of these new agents.AREAS COVERED: We conducted a review of the current literature on public databases (PubMed, ClinicalTrials.gov, and U.S. Food and Drug Administration) regarding new AML drugs that were approved from 2...
Source: Expert Opinion on Drug Safety - November 28, 2023 Category: Drugs & Pharmacology Authors: Mark Dalgetty Christian Leurinda Jorge Cortes Source Type: research
Nail lichen planus treatment safety
Expert Opin Drug Saf. 2023 Nov 28. doi: 10.1080/14740338.2023.2288902. Online ahead of print.ABSTRACTTopical therapies for nail lichen planus (clobetasol propionate, topical tacrolimus, bath-PUVA), intralesional treatment (triamcinolone), and systemic treatment (corticosteroids, retinoids, small molecule inhibitors (jak/stat inhibitors), TNF-alpha inhibitors (etanercept), systemic immunomodulators (oral calcineurin inhibitors, mycophenolate mophetil), and antimalarials (chloroquine), each with unique safety profiles and considerations. Herein, we discuss common and uncommon adverse events, as well as utilization for specia...
Source: Expert Opinion on Drug Safety - November 28, 2023 Category: Drugs & Pharmacology Authors: Eden N Axler Shari R Lipner Source Type: research
A comparative safety review of targeted therapies for acute myeloid leukemia
Expert Opin Drug Saf. 2023 Nov 28. doi: 10.1080/14740338.2023.2289176. Online ahead of print.ABSTRACTINTRODUCTION: Acute myeloid leukemia (AML) treatment has primarily focused on 7 + 3 chemotherapy, but in the last decade there has been a significant increase in new therapies, mostly targeted agents, approved for the treatment of AML. We performed a comparative analysis of the unique safety profile of each of these new agents.AREAS COVERED: We conducted a review of the current literature on public databases (PubMed, ClinicalTrials.gov, and U.S. Food and Drug Administration) regarding new AML drugs that were approved from 2...
Source: Expert Opinion on Drug Safety - November 28, 2023 Category: Drugs & Pharmacology Authors: Mark Dalgetty Christian Leurinda Jorge Cortes Source Type: research
Nail lichen planus treatment safety
Expert Opin Drug Saf. 2023 Nov 28. doi: 10.1080/14740338.2023.2288902. Online ahead of print.ABSTRACTTopical therapies for nail lichen planus (clobetasol propionate, topical tacrolimus, bath-PUVA), intralesional treatment (triamcinolone), and systemic treatment (corticosteroids, retinoids, small molecule inhibitors (jak/stat inhibitors), TNF-alpha inhibitors (etanercept), systemic immunomodulators (oral calcineurin inhibitors, mycophenolate mophetil), and antimalarials (chloroquine), each with unique safety profiles and considerations. Herein, we discuss common and uncommon adverse events, as well as utilization for specia...
Source: Expert Opinion on Drug Safety - November 28, 2023 Category: Drugs & Pharmacology Authors: Eden N Axler Shari R Lipner Source Type: research
